Áleff Mascarenhas Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Áleff Mascarenhas Silva has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alice Campos Meneses
Centro Universitário Alfredo Nasser, Aparecida de Goiânia, Goiânia, Brazil
2 shared publications - Fernanda Cristina Poscai Ribeiro
Universidade do Oeste Paulista, Guarujá, São Paulo, Brazil
2 shared publications - Aracelle Victor Do Carmo Faria
Federal University of Goiás, Goiânia, Brazil
1 shared publication - Fabiana Khauam Marangoni
Protegi clínica infantil, São José do Rio Preto, São Paulo, Brazil
1 shared publication - Felipe Perlingeiro Picard Flores da Cunha
Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
1 shared publication - Kleber Fernando Pereira
Universidade Federal do Paraná, Brazil
1 shared publication
Latest Publications
- 1 November 2025
- Published by Springer Nature in neurogenetics
- Vol. 26 (1) , 1-9
Mecasermin for the treatment of Rett Syndrome: a systematic review
Mecasermin, a recombinant analogue of insulin‑like growth factor 1 (IGF‑1), is under investigation as a potential therapy for Rett syndrome (RTT), a neurodevelopmental disorder resulting from mutations in the MECP2 gene. In this systematic review, we assessed the impact of mecasermin on the full spectrum of RTT severity by screening relevant clinical studies identified through MeSH‑based database queries. Evidence indicates that IGF‑1 administration may help preserve social engagement and cognitive function in RTT, although autonomic control and behavioral outcomes have been inconsistent, and electroencephalographic alterations display considerable heterogeneity. Moreover, transcriptomic analyses have uncovered discrete gene‑expression signatures in molecularly defined patient subgroups, suggesting that genetic background modulates therapeutic response. These findings highlight the promise of mecasermin for ameliorating specific RTT features while underscoring the necessity of larger, rigorously designed trials to refine treatment regimens and implement stratified, patient‑specific approaches.
- 1 November 2025
- Published by Springer Nature in neurogenetics
- Vol. 26 (1) , 1-9
Mecasermin for the treatment of Rett Syndrome: a systematic review
Mecasermin, a recombinant analogue of insulin‑like growth factor 1 (IGF‑1), is under investigation as a potential therapy for Rett syndrome (RTT), a neurodevelopmental disorder resulting from mutations in the MECP2 gene. In this systematic review, we assessed the impact of mecasermin on the full spectrum of RTT severity by screening relevant clinical studies identified through MeSH‑based database queries. Evidence indicates that IGF‑1 administration may help preserve social engagement and cognitive function in RTT, although autonomic control and behavioral outcomes have been inconsistent, and electroencephalographic alterations display considerable heterogeneity. Moreover, transcriptomic analyses have uncovered discrete gene‑expression signatures in molecularly defined patient subgroups, suggesting that genetic background modulates therapeutic response. These findings highlight the promise of mecasermin for ameliorating specific RTT features while underscoring the necessity of larger, rigorously designed trials to refine treatment regimens and implement stratified, patient‑specific approaches.